Canada’s Intellectual Property Firm

May 1 deadline to seek leave to intervene in PMPRB SOLIRIS rehearing

Authored byKatie Lee

As previously reported, the Federal Court of Appeal set aside the Federal Court’s decision dismissing Alexion’s application for judicial review and remitted the matter of whether Alexion’s SOLIRIS (eculizumab) was sold at an excessive price back to the Patented Medicine Prices Review Board (PMPRB or Board) for redetermination. 

On April 1, 2022, the Board announced it will hold a public rehearing of the matter, and that those that wish to participate as an intervener must file a motion for leave to intervene no later than May 1, 2022. The rehearing is scheduled to be held on June 20, 2022.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.